The Medicines Company declares positive results from Inclisiran trial
Category: #health  | By Nikita Chaurasia  | Date: 2019-08-28 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

The Medicines Company declares positive results from Inclisiran trial
  • The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with the findings from Phase 2 and 1 trials.
     
  • The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

The Medicines Company, a biopharmaceutical company dedicated to halt atherosclerosis progression and reduce cardiovascular risk, reportedly announced the positive topline outcomes of the first Phase 3 clinical trial examining the safety, tolerability and efficacy of inclisiran to reduce LDL-cholesterol by taking doses twice a year.

The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with findings from Phase 2 and 1 trials. The trial evaluated that inclisiran was tolerated well and confirmed that its safety profile was as favorable as that shown in the ORION-3 and ORION-1 Phase 2 open-label extension studies.

Detailed safety, tolerability and efficacy data from ORION-11 would be presented at a science session being conducted at the European Society of Cardiology’s ESC Congress 2019 in Paris on the 2nd of September at 8:30 am Central European Time (CET).

Mark Timney, CEO at The Medicines Company stated that it is an important occasion that strengthens the company’s confidence on in the immense potential of inclisiran to radically change cardiovascular disease treatment.

Mark added that he was proud of the company’s clinical development department’s commitment to quickly and efficiently develop this top-quality investigational therapy which could help millions of patients of ASCVD to attain treatment goals, have healthier lives and live longer.

This global study took place at 70 different sites across seven countries, ex-U.S. Each trial participant was given inclisiran sodium 300 mg, initially given as a subcutaneous injection, then again after three months and every six months after first three months.

 

Source Credit: https://www.themedicinescompany.com/investor/pr/3992694/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

McKinsey commences job cuts focused on non-client serving teams

McKinsey commences job cuts focused on non-client serving teams

By Nikita Chaurasia

McKinsey and Co. a consulting giant entity has decided to start cutting jobs in one of the biggest rounds of layoffs for the company. This is likely to eliminate the jobs of about 2000 employees from work. The layoffs will be focused on support st...

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...